Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus
Purpose Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum lev...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2022, Vol.77 (3), p.561-565 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 565 |
|---|---|
| container_issue | 3 |
| container_start_page | 561 |
| container_title | Endocrine |
| container_volume | 77 |
| creator | Kullenberg, Helena Rossen, Jenny Johansson, Unn-Britt Hagströmer, Maria Nyström, Thomas Kumlin, Maria Svedberg, Marie M. |
| description | Purpose
Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum levels of IDE in patients with T2DM.
Method
Blood serum samples were obtained from a biobank. Samples from subjects with T2DM and without metabolic disease were divided into subgroups; lifestyle treatment (
n
= 10), oral antidiabetic treatment (
n
= 17), insulin treatment (
n
= 20) and metabolically healthy controls (
n
= 18). Serum levels of IDE were analysed using specific ELISA assays.
Results
Serum levels of IDE were elevated in subjects with T2DM compared to metabolically healthy individuals (
p
= 0.033). No significant differences were detected between treatment subgroups.
Conclusion
The present study indicates that patients with T2DM have increased serum IDE levels, compared to metabolically healthy individuals. However, for IDE to be clinically useful as a biomarker, its full function and possible use needs to be further elucidated in larger studies showing reproducible outcomes. |
| doi_str_mv | 10.1007/s12020-022-03123-7 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_452514</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2681045504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-14ba261bf229248f1d635b08d6830cef1e9731d2b293b323a6738407c6160a143</originalsourceid><addsrcrecordid>eNp9ksFO3DAQhqOqSKXAC_RkqRekymU8jp3kiGhpkZC4UK6Wk0x2TbNOsBPQ9unxskupkOjJI8_3z_yamSz7JOCrAChOokBA4IDIQQqUvHiX7QulKg4p__6f-EP2McZbSCTqYj-7ufBNIBupZT3dUx_Z0DHn49w7z1taBNs6v2Dk_6xXlBJstJMjP0X24KYlm9YjMWStszVNFNmK-t5NczzM9jrbRzravQfZr_Pv12c_-eXVj4uz00ve5KAnLvLaohZ1h1hhXnai1VLVULa6lNBQJ6gqpGixxkrWEqXVhSxzKBotNFiRy4OMb-vGBxrn2ozBrWxYm8E6s_v6nSIyuUL1xFdv8mMY2hfRs1AoSANGKJP2y5vab-7m1AxhYeJymXrJKtHHWzqVvZspTmblYpPGYz0NczSoSwG5UrAx9fkVejvMwae5GSxA5qoEtWmPW6oJQ4yBur8GBJjNEZjtEZi0WvN0BKZIIrnznGC_oPBS-j-qR-MNtHw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2703458058</pqid></control><display><type>article</type><title>Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus</title><source>Springer Online Journals Complete</source><creator>Kullenberg, Helena ; Rossen, Jenny ; Johansson, Unn-Britt ; Hagströmer, Maria ; Nyström, Thomas ; Kumlin, Maria ; Svedberg, Marie M.</creator><creatorcontrib>Kullenberg, Helena ; Rossen, Jenny ; Johansson, Unn-Britt ; Hagströmer, Maria ; Nyström, Thomas ; Kumlin, Maria ; Svedberg, Marie M.</creatorcontrib><description>Purpose
Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum levels of IDE in patients with T2DM.
Method
Blood serum samples were obtained from a biobank. Samples from subjects with T2DM and without metabolic disease were divided into subgroups; lifestyle treatment (
n
= 10), oral antidiabetic treatment (
n
= 17), insulin treatment (
n
= 20) and metabolically healthy controls (
n
= 18). Serum levels of IDE were analysed using specific ELISA assays.
Results
Serum levels of IDE were elevated in subjects with T2DM compared to metabolically healthy individuals (
p
= 0.033). No significant differences were detected between treatment subgroups.
Conclusion
The present study indicates that patients with T2DM have increased serum IDE levels, compared to metabolically healthy individuals. However, for IDE to be clinically useful as a biomarker, its full function and possible use needs to be further elucidated in larger studies showing reproducible outcomes.</description><identifier>ISSN: 1559-0100</identifier><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-022-03123-7</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Alzheimer's disease ; Brief Report ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Endocrinology ; Enzyme-linked immunosorbent assay ; Enzymes ; Humanities and Social Sciences ; Insulin ; Insulin resistance ; Insulin-degrading enzyme ; Insulysin ; Internal Medicine ; Medicin och hälsovetenskap ; Medicine ; Medicine & Public Health ; Metabolic disorders ; multidisciplinary ; Patients ; Science ; Serum levels ; Type 2 diabetes mellitus</subject><ispartof>Endocrine, 2022, Vol.77 (3), p.561-565</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-14ba261bf229248f1d635b08d6830cef1e9731d2b293b323a6738407c6160a143</citedby><cites>FETCH-LOGICAL-c406t-14ba261bf229248f1d635b08d6830cef1e9731d2b293b323a6738407c6160a143</cites><orcidid>0000-0002-0785-7029</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-022-03123-7$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-022-03123-7$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,315,781,785,886,4025,27928,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:shh:diva-4539$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:150007208$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Kullenberg, Helena</creatorcontrib><creatorcontrib>Rossen, Jenny</creatorcontrib><creatorcontrib>Johansson, Unn-Britt</creatorcontrib><creatorcontrib>Hagströmer, Maria</creatorcontrib><creatorcontrib>Nyström, Thomas</creatorcontrib><creatorcontrib>Kumlin, Maria</creatorcontrib><creatorcontrib>Svedberg, Marie M.</creatorcontrib><title>Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus</title><title>Endocrine</title><addtitle>Endocrine</addtitle><description>Purpose
Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum levels of IDE in patients with T2DM.
Method
Blood serum samples were obtained from a biobank. Samples from subjects with T2DM and without metabolic disease were divided into subgroups; lifestyle treatment (
n
= 10), oral antidiabetic treatment (
n
= 17), insulin treatment (
n
= 20) and metabolically healthy controls (
n
= 18). Serum levels of IDE were analysed using specific ELISA assays.
Results
Serum levels of IDE were elevated in subjects with T2DM compared to metabolically healthy individuals (
p
= 0.033). No significant differences were detected between treatment subgroups.
Conclusion
The present study indicates that patients with T2DM have increased serum IDE levels, compared to metabolically healthy individuals. However, for IDE to be clinically useful as a biomarker, its full function and possible use needs to be further elucidated in larger studies showing reproducible outcomes.</description><subject>Alzheimer's disease</subject><subject>Brief Report</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Endocrinology</subject><subject>Enzyme-linked immunosorbent assay</subject><subject>Enzymes</subject><subject>Humanities and Social Sciences</subject><subject>Insulin</subject><subject>Insulin resistance</subject><subject>Insulin-degrading enzyme</subject><subject>Insulysin</subject><subject>Internal Medicine</subject><subject>Medicin och hälsovetenskap</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Metabolic disorders</subject><subject>multidisciplinary</subject><subject>Patients</subject><subject>Science</subject><subject>Serum levels</subject><subject>Type 2 diabetes mellitus</subject><issn>1559-0100</issn><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9ksFO3DAQhqOqSKXAC_RkqRekymU8jp3kiGhpkZC4UK6Wk0x2TbNOsBPQ9unxskupkOjJI8_3z_yamSz7JOCrAChOokBA4IDIQQqUvHiX7QulKg4p__6f-EP2McZbSCTqYj-7ufBNIBupZT3dUx_Z0DHn49w7z1taBNs6v2Dk_6xXlBJstJMjP0X24KYlm9YjMWStszVNFNmK-t5NczzM9jrbRzravQfZr_Pv12c_-eXVj4uz00ve5KAnLvLaohZ1h1hhXnai1VLVULa6lNBQJ6gqpGixxkrWEqXVhSxzKBotNFiRy4OMb-vGBxrn2ozBrWxYm8E6s_v6nSIyuUL1xFdv8mMY2hfRs1AoSANGKJP2y5vab-7m1AxhYeJymXrJKtHHWzqVvZspTmblYpPGYz0NczSoSwG5UrAx9fkVejvMwae5GSxA5qoEtWmPW6oJQ4yBur8GBJjNEZjtEZi0WvN0BKZIIrnznGC_oPBS-j-qR-MNtHw</recordid><startdate>2022</startdate><enddate>2022</enddate><creator>Kullenberg, Helena</creator><creator>Rossen, Jenny</creator><creator>Johansson, Unn-Britt</creator><creator>Hagströmer, Maria</creator><creator>Nyström, Thomas</creator><creator>Kumlin, Maria</creator><creator>Svedberg, Marie M.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>DF4</scope><orcidid>https://orcid.org/0000-0002-0785-7029</orcidid></search><sort><creationdate>2022</creationdate><title>Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus</title><author>Kullenberg, Helena ; Rossen, Jenny ; Johansson, Unn-Britt ; Hagströmer, Maria ; Nyström, Thomas ; Kumlin, Maria ; Svedberg, Marie M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-14ba261bf229248f1d635b08d6830cef1e9731d2b293b323a6738407c6160a143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Alzheimer's disease</topic><topic>Brief Report</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Endocrinology</topic><topic>Enzyme-linked immunosorbent assay</topic><topic>Enzymes</topic><topic>Humanities and Social Sciences</topic><topic>Insulin</topic><topic>Insulin resistance</topic><topic>Insulin-degrading enzyme</topic><topic>Insulysin</topic><topic>Internal Medicine</topic><topic>Medicin och hälsovetenskap</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Metabolic disorders</topic><topic>multidisciplinary</topic><topic>Patients</topic><topic>Science</topic><topic>Serum levels</topic><topic>Type 2 diabetes mellitus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kullenberg, Helena</creatorcontrib><creatorcontrib>Rossen, Jenny</creatorcontrib><creatorcontrib>Johansson, Unn-Britt</creatorcontrib><creatorcontrib>Hagströmer, Maria</creatorcontrib><creatorcontrib>Nyström, Thomas</creatorcontrib><creatorcontrib>Kumlin, Maria</creatorcontrib><creatorcontrib>Svedberg, Marie M.</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Sophiahemmet Högskola</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kullenberg, Helena</au><au>Rossen, Jenny</au><au>Johansson, Unn-Britt</au><au>Hagströmer, Maria</au><au>Nyström, Thomas</au><au>Kumlin, Maria</au><au>Svedberg, Marie M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><date>2022</date><risdate>2022</risdate><volume>77</volume><issue>3</issue><spage>561</spage><epage>565</epage><pages>561-565</pages><issn>1559-0100</issn><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>Purpose
Decreasing levels of serum insulin-degrading enzyme (IDE) have been associated with an increased risk for Alzheimer´s disease (AD) in patients with type 2 diabetes mellitus (T2DM). Research on serum IDE levels in patients with T2DM is sparse and the aim of this study was to explore serum levels of IDE in patients with T2DM.
Method
Blood serum samples were obtained from a biobank. Samples from subjects with T2DM and without metabolic disease were divided into subgroups; lifestyle treatment (
n
= 10), oral antidiabetic treatment (
n
= 17), insulin treatment (
n
= 20) and metabolically healthy controls (
n
= 18). Serum levels of IDE were analysed using specific ELISA assays.
Results
Serum levels of IDE were elevated in subjects with T2DM compared to metabolically healthy individuals (
p
= 0.033). No significant differences were detected between treatment subgroups.
Conclusion
The present study indicates that patients with T2DM have increased serum IDE levels, compared to metabolically healthy individuals. However, for IDE to be clinically useful as a biomarker, its full function and possible use needs to be further elucidated in larger studies showing reproducible outcomes.</abstract><cop>New York</cop><pub>Springer US</pub><doi>10.1007/s12020-022-03123-7</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-0785-7029</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1559-0100 |
| ispartof | Endocrine, 2022, Vol.77 (3), p.561-565 |
| issn | 1559-0100 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_452514 |
| source | Springer Online Journals Complete |
| subjects | Alzheimer's disease Brief Report Diabetes Diabetes mellitus (non-insulin dependent) Endocrinology Enzyme-linked immunosorbent assay Enzymes Humanities and Social Sciences Insulin Insulin resistance Insulin-degrading enzyme Insulysin Internal Medicine Medicin och hälsovetenskap Medicine Medicine & Public Health Metabolic disorders multidisciplinary Patients Science Serum levels Type 2 diabetes mellitus |
| title | Increased levels of insulin-degrading enzyme in patients with type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T12%3A46%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Increased%20levels%20of%20insulin-degrading%20enzyme%20in%20patients%20with%20type%202%20diabetes%20mellitus&rft.jtitle=Endocrine&rft.au=Kullenberg,%20Helena&rft.date=2022&rft.volume=77&rft.issue=3&rft.spage=561&rft.epage=565&rft.pages=561-565&rft.issn=1559-0100&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-022-03123-7&rft_dat=%3Cproquest_swepu%3E2681045504%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2703458058&rft_id=info:pmid/&rfr_iscdi=true |